Persistent <i>in vitro</i> nociceptor hyperexcitability and axonal retraction produced by repeated paclitaxel doses

Paclitaxel-induced peripheral neuropathy is a common, clinically relevant sensory side effect that may lead to chemotherapy dose reduction or cessation, compromising patient survival. The neuropathy may persist for more than 6 months, suggesting lasting effects on peripheral nociceptor endings. The mechanisms underlying these persistent nociceptive alterations remain poorly explored. Here, we developed a nociceptor primary culture from adult mice to assess the effects of two 24 h (h) paclitaxel incubations separated by a 96 h recovery period, mimicking chemotherapy cycles. Repeated dosing of paclitaxel produced persistent, spontaneous and evoked hyperexcitability, and axonal retraction. The first paclitaxel incubation promoted a reversible axonopathy with increased spontaneous and evoked electrogenicity that peaked 48-h post-treatment and resolved 96 h after treatment. Notably, the second paclitaxel instillation produced severe and persistent axonal degeneration. In addition, it promoted strong, long-lasting, spontaneous and evoked excitability, particularly in IB4 (-) sensory neurons. Enhanced neuronal excitability was ascribed to increased depolarization spontaneous fluctuations (DFSs) of the membrane potential and elevated somal input resistance. These changes are likely mediated by the upregulation of Na<sub>V</sub>1.8 and TRPV1 channels following paclitaxel administration. Furthermore, repeated exposure to the drug resulted in additional upregulation of TRPM8, TRPA1, and K<sub>V</sub>3.4 channels. Therefore, our findings support Na<sub>V</sub>1.8 and TRPV1 as important therapeutic targets for alleviating or preventing neuropathic symptoms induced by paclitaxel. Additionally, these results validate the application of long-term nociceptor primary cultures as preclinical models to investigate the cumulative neurotoxicity of chemotherapeutic agents, as well as to evaluate interventions that promote axonal regeneration and decrease hyperexcitability.

Authors

Institutions

Publication Details

Journal
FEBS Journal
Published
2026-03-28
DOI
https://doi.org/10.1111/febs.70517
Primary Topic
Cancer Treatment and Pharmacology
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Persistent in vitro nociceptor hyperexcitability and axonal retraction produced by repeated paclitaxel doses

Antonio Ferrer‐Montiel, Asia Fernández‐Carvajal, Virginia Lozano, Angela Lamberti
FEBS Journal
Cancer Treatment and Pharmacology
article

Persistent in vitro nociceptor hyperexcitability and axonal retraction produced by repeated paclitaxel doses

Antonio Ferrer‐Montiel, Asia Fernández‐Carvajal, Virginia Lozano, Angela Lamberti
article en

Abstract

Paclitaxel-induced peripheral neuropathy is a common, clinically relevant sensory side effect that may lead to chemotherapy dose reduction or cessation, compromising patient survival. The neuropathy may persist for more than 6 months, suggesting lasting effects on peripheral nociceptor endings. The mechanisms underlying these persistent nociceptive alterations remain poorly explored. Here, we developed a nociceptor primary culture from adult mice to assess the effects of two 24 h (h) paclitaxel incubations separated by a 96 h recovery period, mimicking chemotherapy cycles. Repeated dosing of paclitaxel produced persistent, spontaneous and evoked hyperexcitability, and axonal retraction. The first paclitaxel incubation promoted a reversible axonopathy with increased spontaneous and evoked electrogenicity that peaked 48-h post-treatment and resolved 96 h after treatment. Notably, the second paclitaxel instillation produced severe and persistent axonal degeneration. In addition, it promoted strong, long-lasting, spontaneous and evoked excitability, particularly in IB4 (-) sensory neurons. Enhanced neuronal excitability was ascribed to increased depolarization spontaneous fluctuations (DFSs) of the membrane potential and elevated somal input resistance. These changes are likely mediated by the upregulation of Na<sub>V</sub>1.8 and TRPV1 channels following paclitaxel administration. Furthermore, repeated exposure to the drug resulted in additional upregulation of TRPM8, TRPA1, and K<sub>V</sub>3.4 channels. Therefore, our findings support Na<sub>V</sub>1.8 and TRPV1 as important therapeutic targets for alleviating or preventing neuropathic symptoms induced by paclitaxel. Additionally, these results validate the application of long-term nociceptor primary cultures as preclinical models to investigate the cumulative neurotoxicity of chemotherapeutic agents, as well as to evaluate interventions that promote axonal regeneration and decrease hyperexcitability.

FEBS Journal
Universitat de Miguel Hernández d'Elx (ES)
Good health and well-being
Openalex Percentile: Top 4%
Cancer Treatment and Pharmacology
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.